A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

NCT04465890 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis b

Interventions

DRUG: ASC22
DRUG: sodium chloride

Sponsor

Ascletis Pharmaceuticals Co., Ltd.

Collaborators

[object Object]
[object Object]